Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications... Show more
Industry Biotechnology
A.I.dvisor indicates that over the last year, CMVLF has been loosely correlated with TENX. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if CMVLF jumps, then TENX could also see price increases.
| Ticker / NAME | Correlation To CMVLF | 1D Price Change % | ||
|---|---|---|---|---|
| CMVLF | 100% | N/A | ||
| TENX - CMVLF | 56% Loosely correlated | -0.98% | ||
| SBHMY - CMVLF | 51% Loosely correlated | +7.36% | ||
| AURA - CMVLF | 30% Poorly correlated | +2.41% | ||
| ALDX - CMVLF | 23% Poorly correlated | -4.96% | ||
| TARS - CMVLF | 23% Poorly correlated | -2.21% | ||
More | ||||